Publication Name	World Journal of Clinical Oncology
Manuscript ID	42964
Country	United States

Received	2018-11-08 03:27
Peer-Review Started	2018-11-10 08:22
To Make the First Decision	2018-11-20 04:06
Return for Revision	2018-11-29 01:26
Revised	2018-12-27 21:35
Second Decision	2019-01-08 12:57
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2019-01-09 03:56
Articles in Press	2019-01-09 03:56
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2019-02-23 09:13
Publish the Manuscript Online	2019-03-22 11:26

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Clinical Trials Study
Article Title	Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Jennifer Wu, Merly Contratto, Krishna P Shanbhogue, Gulam A Manji, Bert H O'Neil, Anne Noonan, Robert Tudor and Ray Lee
Funding Agency and Grant Number
Corresponding Author	Jennifer Wu, MD, Associate Professor, Attending Doctor, Division of Hematology and Oncology, Perlmutter Cancer Center, New York University School of Medicine, 462 First Ave, BCD556, New York, NY 10016, United States. jennifer.wu@nyumc.org
Key Words	Hepatocellular carcinoma; Hypoxia-inducible factor 1α; RO7070179, Super-responder; Dynamic contrast-enhanced-magnetic resonance imaging
Core Tip	Overexpression of hypoxia-inducible factor 1α (HIF-1α) correlates with poor prognosis in hepatocellular carcinoma (HCC) patients. HIF-1a inhibitor decreases HIF-1a mRNA and its downstream targets, it could be a potential treatment in HCC.
Publish Date	2019-03-22 11:26
Citation	Wu J, Contratto M, Shanbhogue KP, Manji GA, O’Neil BH, Noonan A, Tudor R, Lee R. Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma. World J Clin Oncol 2019; 10(3): 149-160
URL	https://www.wjgnet.com/2218-4333/full/v10/i3/149.htm
DOI	https://dx.doi.org/10.5306/wjco.v10.i3.149

Full Article (PDF)	WJCO-10-149.pdf
Full Article (Word)	WJCO-10-149.docx
CONSORT 2010 Statement	42964-CONSORT 2010 Statement.pdf
Manuscript File	42964-Review.docx
Answering Reviewers	42964-Answering reviewers.pdf
Audio Core Tip	42964-Audio core tip.mp3
Clinical Trial Registration Statement	42964-Clinical trial registration statement.pdf
Conflict-of-Interest Disclosure Form	42964-Conflict-of-interest statement.pdf
Copyright License Agreement	42964-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	42964-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	42964-Institutional review board statement.pdf
Peer-review Report	42964-Peer-review(s).pdf
Scientific Misconduct Check	42964-Scientific misconduct check.pdf
Scientific Editor Work List	42964-Scientific editor work list.pdf